Latest Breaking News On - Sukaina virji - Page 5 : comparemela.com

Mironid extends Series A round raising £35 million to date for development of first-in-class small molecules to treat life-threatening hereditary kidney disease

Achilles Therapeutics to Present at Upcoming Conferences

12.06.2023 - LONDON, June 12, 2023 (GLOBE NEWSWIRE) - Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking .

Achilles Therapeutics PLC: Achilles Therapeutics' New Immunogenicity Prediction Application of its AI-Powered PELEUS Platform Uniquely Identifies the Most Potent T Cell Antigens

- New AI module delivers a "Target-to-T cell" approach for revolutionizing the identification and prioritization of targets for personalized antigen approaches -LONDON, May 10, 2023 (GLOBE NEWSWIRE)

Achilles Therapeutics Reports First Quarter 2023 Financial

- Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of.

Achilles Therapeutics PLC: Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient's tumor - - Patent applies to any modality, including vaccine and